Gene therapy with B7.1 and GM-CSF vaccines in a murine AML model
Characterization of B7.1 and GM-CSF vaccines on the induction of anti-tumor immunity in a murine AML model. Primary AML cells were retrovirally transduced with the murine costimulatory molecule B7.1, a natural ligand for the T-cell receptors CD28 and CTLA-4, or the cytokine GM-CSF. Mice were vaccina...
Gespeichert in:
| Veröffentlicht in: | Journal of pediatric hematology/oncology 1997-11, Vol.19 (6), p.536-540 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 540 |
|---|---|
| container_issue | 6 |
| container_start_page | 536 |
| container_title | Journal of pediatric hematology/oncology |
| container_volume | 19 |
| creator | DUNUSSI-JOANNOPOULOS, K WEINSTEIN, H. J ARCECI, R. J CROOP, J. M |
| description | Characterization of B7.1 and GM-CSF vaccines on the induction of anti-tumor immunity in a murine AML model.
Primary AML cells were retrovirally transduced with the murine costimulatory molecule B7.1, a natural ligand for the T-cell receptors CD28 and CTLA-4, or the cytokine GM-CSF. Mice were vaccinated with irradiated AML cells expressing B7.1 or GM-CSF before or after inoculation of wild type AML cells.
Intravenous injection of irradiated B7.1 or GM-CSF expressing AML cells can provide long lasting systemic immunity against a subsequent challenge of wild type AML cells. Vaccination with irradiated B7.1 or GM-CSF expressing AML cells results in rejection of established leukemia when the vaccination occurs in the early stages of the disease. However, when the vaccines are administered > 2 weeks after leukemic inoculation, only mice which receive the GM-CSF vaccine are cured of leukemia.
These results suggest that tumor burden and vaccine efficiency are most likely to be the limiting factors in the curative potential of tumor vaccines. Novel approaches such as this experiment could provide improved therapeutic outcomes in patients with AML and other cancers. |
| doi_str_mv | 10.1097/00043426-199711000-00012 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_79480544</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>79480544</sourcerecordid><originalsourceid>FETCH-LOGICAL-c339t-8c76e0c201d0294fbf7d27b4f057e1b3d49dbfee690c2b4b239761c309b0944c3</originalsourceid><addsrcrecordid>eNo9kMtOwzAQRS0EKqXwCUheIHYp40fieEepaEFqxQJYW7bjqEF5FDsF9e8xNHRh2aM5d0Y-CGECUwJS3AEAZ5xmCZFSEBLLJB5CT9CYpCxLWCby0_gGIRJOCD9HFyF8RELE1AiNJAchOR2j-6VrHe43zuvtHn9X_QY_iCnBui3wcp3MXxf4S1tbtS7gqsUaNzsfCzxbr3DTFa6-RGelroO7Gu4Jel88vs2fktXL8nk-WyWWMdknuRWZA0uBFEAlL00pCioMLyEVjhhWcFmY0rlMRshwQ5kUGbEMpAHJuWUTdHuYu_Xd586FXjVVsK6udeu6XVDxOzmknEcwP4DWdyF4V6qtrxrt94qA-pWn_uWpozz1Jy9Gr4cdO9O44hgcbMX-zdDXweq69Lq1VThiFPIoP2U_3hdzNw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>79480544</pqid></control><display><type>article</type><title>Gene therapy with B7.1 and GM-CSF vaccines in a murine AML model</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>DUNUSSI-JOANNOPOULOS, K ; WEINSTEIN, H. J ; ARCECI, R. J ; CROOP, J. M</creator><creatorcontrib>DUNUSSI-JOANNOPOULOS, K ; WEINSTEIN, H. J ; ARCECI, R. J ; CROOP, J. M</creatorcontrib><description>Characterization of B7.1 and GM-CSF vaccines on the induction of anti-tumor immunity in a murine AML model.
Primary AML cells were retrovirally transduced with the murine costimulatory molecule B7.1, a natural ligand for the T-cell receptors CD28 and CTLA-4, or the cytokine GM-CSF. Mice were vaccinated with irradiated AML cells expressing B7.1 or GM-CSF before or after inoculation of wild type AML cells.
Intravenous injection of irradiated B7.1 or GM-CSF expressing AML cells can provide long lasting systemic immunity against a subsequent challenge of wild type AML cells. Vaccination with irradiated B7.1 or GM-CSF expressing AML cells results in rejection of established leukemia when the vaccination occurs in the early stages of the disease. However, when the vaccines are administered > 2 weeks after leukemic inoculation, only mice which receive the GM-CSF vaccine are cured of leukemia.
These results suggest that tumor burden and vaccine efficiency are most likely to be the limiting factors in the curative potential of tumor vaccines. Novel approaches such as this experiment could provide improved therapeutic outcomes in patients with AML and other cancers.</description><identifier>ISSN: 1077-4114</identifier><identifier>EISSN: 1536-3678</identifier><identifier>DOI: 10.1097/00043426-199711000-00012</identifier><identifier>PMID: 9407942</identifier><identifier>CODEN: JPHOFG</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott</publisher><subject>Animals ; B7-1 Antigen - biosynthesis ; B7-1 Antigen - immunology ; B7-1 Antigen - therapeutic use ; Biological and medical sciences ; Cancer Vaccines - immunology ; Cancer Vaccines - pharmacology ; Disease Models, Animal ; Genetic Therapy - methods ; Granulocyte-Macrophage Colony-Stimulating Factor - biosynthesis ; Granulocyte-Macrophage Colony-Stimulating Factor - immunology ; Hematologic and hematopoietic diseases ; Leukemia, Myeloid, Acute - immunology ; Leukemia, Myeloid, Acute - metabolism ; Leukemia, Myeloid, Acute - therapy ; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis ; Medical sciences ; Mice ; Other treatments ; Treatment. General aspects ; Tumors</subject><ispartof>Journal of pediatric hematology/oncology, 1997-11, Vol.19 (6), p.536-540</ispartof><rights>1998 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c339t-8c76e0c201d0294fbf7d27b4f057e1b3d49dbfee690c2b4b239761c309b0944c3</citedby><cites>FETCH-LOGICAL-c339t-8c76e0c201d0294fbf7d27b4f057e1b3d49dbfee690c2b4b239761c309b0944c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2081535$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9407942$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>DUNUSSI-JOANNOPOULOS, K</creatorcontrib><creatorcontrib>WEINSTEIN, H. J</creatorcontrib><creatorcontrib>ARCECI, R. J</creatorcontrib><creatorcontrib>CROOP, J. M</creatorcontrib><title>Gene therapy with B7.1 and GM-CSF vaccines in a murine AML model</title><title>Journal of pediatric hematology/oncology</title><addtitle>J Pediatr Hematol Oncol</addtitle><description>Characterization of B7.1 and GM-CSF vaccines on the induction of anti-tumor immunity in a murine AML model.
Primary AML cells were retrovirally transduced with the murine costimulatory molecule B7.1, a natural ligand for the T-cell receptors CD28 and CTLA-4, or the cytokine GM-CSF. Mice were vaccinated with irradiated AML cells expressing B7.1 or GM-CSF before or after inoculation of wild type AML cells.
Intravenous injection of irradiated B7.1 or GM-CSF expressing AML cells can provide long lasting systemic immunity against a subsequent challenge of wild type AML cells. Vaccination with irradiated B7.1 or GM-CSF expressing AML cells results in rejection of established leukemia when the vaccination occurs in the early stages of the disease. However, when the vaccines are administered > 2 weeks after leukemic inoculation, only mice which receive the GM-CSF vaccine are cured of leukemia.
These results suggest that tumor burden and vaccine efficiency are most likely to be the limiting factors in the curative potential of tumor vaccines. Novel approaches such as this experiment could provide improved therapeutic outcomes in patients with AML and other cancers.</description><subject>Animals</subject><subject>B7-1 Antigen - biosynthesis</subject><subject>B7-1 Antigen - immunology</subject><subject>B7-1 Antigen - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Cancer Vaccines - immunology</subject><subject>Cancer Vaccines - pharmacology</subject><subject>Disease Models, Animal</subject><subject>Genetic Therapy - methods</subject><subject>Granulocyte-Macrophage Colony-Stimulating Factor - biosynthesis</subject><subject>Granulocyte-Macrophage Colony-Stimulating Factor - immunology</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Leukemia, Myeloid, Acute - immunology</subject><subject>Leukemia, Myeloid, Acute - metabolism</subject><subject>Leukemia, Myeloid, Acute - therapy</subject><subject>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>Other treatments</subject><subject>Treatment. General aspects</subject><subject>Tumors</subject><issn>1077-4114</issn><issn>1536-3678</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1997</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kMtOwzAQRS0EKqXwCUheIHYp40fieEepaEFqxQJYW7bjqEF5FDsF9e8xNHRh2aM5d0Y-CGECUwJS3AEAZ5xmCZFSEBLLJB5CT9CYpCxLWCby0_gGIRJOCD9HFyF8RELE1AiNJAchOR2j-6VrHe43zuvtHn9X_QY_iCnBui3wcp3MXxf4S1tbtS7gqsUaNzsfCzxbr3DTFa6-RGelroO7Gu4Jel88vs2fktXL8nk-WyWWMdknuRWZA0uBFEAlL00pCioMLyEVjhhWcFmY0rlMRshwQ5kUGbEMpAHJuWUTdHuYu_Xd586FXjVVsK6udeu6XVDxOzmknEcwP4DWdyF4V6qtrxrt94qA-pWn_uWpozz1Jy9Gr4cdO9O44hgcbMX-zdDXweq69Lq1VThiFPIoP2U_3hdzNw</recordid><startdate>19971101</startdate><enddate>19971101</enddate><creator>DUNUSSI-JOANNOPOULOS, K</creator><creator>WEINSTEIN, H. J</creator><creator>ARCECI, R. J</creator><creator>CROOP, J. M</creator><general>Lippincott</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19971101</creationdate><title>Gene therapy with B7.1 and GM-CSF vaccines in a murine AML model</title><author>DUNUSSI-JOANNOPOULOS, K ; WEINSTEIN, H. J ; ARCECI, R. J ; CROOP, J. M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c339t-8c76e0c201d0294fbf7d27b4f057e1b3d49dbfee690c2b4b239761c309b0944c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1997</creationdate><topic>Animals</topic><topic>B7-1 Antigen - biosynthesis</topic><topic>B7-1 Antigen - immunology</topic><topic>B7-1 Antigen - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Cancer Vaccines - immunology</topic><topic>Cancer Vaccines - pharmacology</topic><topic>Disease Models, Animal</topic><topic>Genetic Therapy - methods</topic><topic>Granulocyte-Macrophage Colony-Stimulating Factor - biosynthesis</topic><topic>Granulocyte-Macrophage Colony-Stimulating Factor - immunology</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Leukemia, Myeloid, Acute - immunology</topic><topic>Leukemia, Myeloid, Acute - metabolism</topic><topic>Leukemia, Myeloid, Acute - therapy</topic><topic>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>Other treatments</topic><topic>Treatment. General aspects</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>DUNUSSI-JOANNOPOULOS, K</creatorcontrib><creatorcontrib>WEINSTEIN, H. J</creatorcontrib><creatorcontrib>ARCECI, R. J</creatorcontrib><creatorcontrib>CROOP, J. M</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of pediatric hematology/oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>DUNUSSI-JOANNOPOULOS, K</au><au>WEINSTEIN, H. J</au><au>ARCECI, R. J</au><au>CROOP, J. M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Gene therapy with B7.1 and GM-CSF vaccines in a murine AML model</atitle><jtitle>Journal of pediatric hematology/oncology</jtitle><addtitle>J Pediatr Hematol Oncol</addtitle><date>1997-11-01</date><risdate>1997</risdate><volume>19</volume><issue>6</issue><spage>536</spage><epage>540</epage><pages>536-540</pages><issn>1077-4114</issn><eissn>1536-3678</eissn><coden>JPHOFG</coden><abstract>Characterization of B7.1 and GM-CSF vaccines on the induction of anti-tumor immunity in a murine AML model.
Primary AML cells were retrovirally transduced with the murine costimulatory molecule B7.1, a natural ligand for the T-cell receptors CD28 and CTLA-4, or the cytokine GM-CSF. Mice were vaccinated with irradiated AML cells expressing B7.1 or GM-CSF before or after inoculation of wild type AML cells.
Intravenous injection of irradiated B7.1 or GM-CSF expressing AML cells can provide long lasting systemic immunity against a subsequent challenge of wild type AML cells. Vaccination with irradiated B7.1 or GM-CSF expressing AML cells results in rejection of established leukemia when the vaccination occurs in the early stages of the disease. However, when the vaccines are administered > 2 weeks after leukemic inoculation, only mice which receive the GM-CSF vaccine are cured of leukemia.
These results suggest that tumor burden and vaccine efficiency are most likely to be the limiting factors in the curative potential of tumor vaccines. Novel approaches such as this experiment could provide improved therapeutic outcomes in patients with AML and other cancers.</abstract><cop>Hagerstown, MD</cop><pub>Lippincott</pub><pmid>9407942</pmid><doi>10.1097/00043426-199711000-00012</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1077-4114 |
| ispartof | Journal of pediatric hematology/oncology, 1997-11, Vol.19 (6), p.536-540 |
| issn | 1077-4114 1536-3678 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_79480544 |
| source | MEDLINE; Journals@Ovid Complete |
| subjects | Animals B7-1 Antigen - biosynthesis B7-1 Antigen - immunology B7-1 Antigen - therapeutic use Biological and medical sciences Cancer Vaccines - immunology Cancer Vaccines - pharmacology Disease Models, Animal Genetic Therapy - methods Granulocyte-Macrophage Colony-Stimulating Factor - biosynthesis Granulocyte-Macrophage Colony-Stimulating Factor - immunology Hematologic and hematopoietic diseases Leukemia, Myeloid, Acute - immunology Leukemia, Myeloid, Acute - metabolism Leukemia, Myeloid, Acute - therapy Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Medical sciences Mice Other treatments Treatment. General aspects Tumors |
| title | Gene therapy with B7.1 and GM-CSF vaccines in a murine AML model |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T17%3A46%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Gene%20therapy%20with%20B7.1%20and%20GM-CSF%20vaccines%20in%20a%20murine%20AML%20model&rft.jtitle=Journal%20of%20pediatric%20hematology/oncology&rft.au=DUNUSSI-JOANNOPOULOS,%20K&rft.date=1997-11-01&rft.volume=19&rft.issue=6&rft.spage=536&rft.epage=540&rft.pages=536-540&rft.issn=1077-4114&rft.eissn=1536-3678&rft.coden=JPHOFG&rft_id=info:doi/10.1097/00043426-199711000-00012&rft_dat=%3Cproquest_cross%3E79480544%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=79480544&rft_id=info:pmid/9407942&rfr_iscdi=true |